Skip to main content
. Author manuscript; available in PMC: 2014 Sep 14.
Published in final edited form as: Breast Cancer Res Treat. 2013 Sep 14;141(2):287–297. doi: 10.1007/s10549-013-2690-z

Table 2.

TGF-β signaling pathway genes: overall associations with breast cancer risk, the breast cancer health disparities study

Gene (SNP) Genotype Controls (n= 4,209)
Cases (n= 3,524)
ORa (95 % CI) pb
N (%) N (%)
RUNX1 (rs7279383) CC 3,098 73.6 2,647 75.1 1.00 0.032 (0.23)
CG/GG 1,110 26.4 876 24.9 0.89 (0.80, 0.99)
RUNX1 (rs8127225) TT 2,591 61.6 2,117 60.1 1.00 0.029 (0.23)
TC/CC 1,612 38.4 1,407 39.9 1.11 (1.01, 1.22)
RUNX2 (rs10948238) CC/CT 3,602 85.6 2,950 83.8 1.00 0.028 (0.42)
TT 604 14.4 571 16.2 1.15 (1.01, 1.30)
RUNX2 (rs13201287) GG/GA 3,899 92.6 3,226 91.5 1.00 0.050 (0.69)
AA 310 7.4 298 8.5 1.18 (1.00, 1.39)
RUNX3 (rs906296) CC 2,701 64.2 2,143 60.8 1.00 0.004 (0.03)
CG/GG 1,505 35.8 1,379 39.2 1.15 (1.04, 1.26)
TGF-β1 (rs4803455) CC 1,400 35.3 1,193 37.0 1.00 0.023 (0.04)
CA/AA 2,561 64.7 2,032 63.0 0.89 (0.81, 0.98)
TGF-β2 (rs6604609)c TT 3,455 82.1 3,009 85.4 1.00 0.0002
TA/AA 753 17.9 515 14.6 0.80 (0.71, 0.91)
TGF-βR1 (rs6478974) TT/TA 3,531 83.9 2,884 81.9 1.00 0.045 (0.19)
AA 677 16.1 639 18.1 1.13 (1.00, 1.28)
TGF-βR2 (rs3773644)c CC/CT 3,767 89.5 3,072 87.2 1.00 0.004
TT 441 10.5 452 12.8 1.21 (1.05, 1.40)
TGF-βR3 (rs6678564) GG 3,523 83.7 3,004 85.2 1.00 0.03 (0.11)
GC/CC 685 16.3 520 14.8 0.87 (0.77, 0.99)

Bold text designates significant associations at the 0.05 level after adjustment for multiple comparisons

a

Adjusted for age, study center, and genetic admixture

b

Wald p-value for 1 df test; p-value adjusted for multiple comparisons (Bonferroni–Holm) in parentheses

c

Only one SNP evaluated for each gene, multiple comparisons not applicable